CISYS LifeSciences News
12/13/2017 - ARO - eClinical Solutions
Academic Research Organizations and their employees are key components of the continued success of all pharmaceutical research. These organizations, mostly non-profit, provide the therapeutic expertise, Investigational Product (IP) knowledge, and patient access that is mandatory for a successful clinical trial. While their contributions are vast, little attention has been focused on meeting the specialized eClinical solutions needs of this market. Some AROs, with little funding build solutions internally and struggle because of the ongoing resources required to build/support these solutions. Others will try and adopt solutions targeted for the sponsor and CRO markets, frequently becoming frustrated trying to customize these solutions to meet their requirements, both functionally and financially.
At CISYS LifeSciences, we have a dedicated team focused on meeting the solution requirements of AROs. Whether your need is to enhance/support an existing solution, develop a new solution or configure one of our Sequence Platform modules to meet your requirements, CISYS Life Sciences has the expertise and solutions to meet the specific of the ARO market. For more information email us at email@example.com.
12/11/2017 - eClinical Cost Reduction
Searching for ways to reduce the rising costs of the eClinical solutions needed to support your clinical trials? Whether you utilize external vendors or have developed your own solutions, CISYS can help you improve efficiencies and reduce costs. CISYS LifeSciences is dedicated to the development of eClinical solutions, our own and the ones developed by our clients. Our experts can analyze your current solutions and help identify opportunities for improvement or suggest other options. CISYS has partnered with research organizations of all sizes to provide, build, or modify their eClinical solutions. If you are looking to make your eClinical solutions more effective while reducing the cost, we can help. If you are interested but have heard this before, we are happy to provide references in advance.
11/15/17 Clinical Adjudication - Two Major Contributors to Increased Costs and Timelines
Today, clinical event/endpoint adjudication has become a key element of post approval safety and Phase II/III clinical trials. As adjudication requirements have increased so has the need for variations in specialized review and committee workflow. Today sponsors and CROs have two choices, one is to implement work arounds in their current electronic solution or switch to a paper process. Both options increase the risks, costs and timelines associated with adjudication. As the number of studies and post approval products requiring adjudication has increased so has the number of clinical events that need to be considered for adjudication. Most adjudication solutions today do not have an internal SMQ process that automatically routes events through the appropriate committee review process, instead they depend on manual intervention that can be inconsistent, inaccurate and time consuming. If you would like to hear more about an adjudication solution with configurable/flexible workflows and internal SMQ functionality contact CISYS LifeSciences (firstname.lastname@example.org or 919-840-1436 ext. 240) to schedule a time to discuss WebEAS and how it will increase productivity and decrease costs.
10/31/17 -- CISYS LifeSciences “WebCode” is the preferred dsNavigator replacement Medical Coding solution at top CROs globally.
There are three components to a successful migration from dsNavigator, without each component replacement technologies won’t be effective long term. At CISYS LifeSciences we take pride in helping our customers make a smooth transition to WebCode for new and legacy studies.
· Technology - CISYS LifeSciences is a certified provider for all UMC formats. WebCode is the most feature rich Medical Coding Solution on the market. WebCode improves the current functionality/efficiency offered by dsNavigator, allowing our customers big and small to improve their coding accuracy and processes.
· ROI - CISYS LifeSciences is taking the bite out of eClinical Solution costs by offering an additional cost model utilizing a “Perpetual License Model”. This model complements our existing per seat and per study models, allowing our customers to pay a one-time license fee (per user). With the Perpetual License model, our customers average a 50% solution savings over 5 years and a 22% increase in coding efficiency.
· Legacy Study Transfer – If your organization is concerned about medical coding options due to the termination of dsNavigator, CISYS LifeSciences has additional services available for downloading, storing and transferring your legacy studies into WebCode.
If you need to replace/improve your coding solution call us at 919 870 1436 ext. 240 or email email@example.com and we can provide additional information, references and budgets to insure your medical coding continues uninterrupted.
7/13/17 -- CISYS WebCode Recertified by UMC for B3 Format
CISYS has been recertified by UMC for the B3 format of WHO DDE, making CISYS’ Sequence WedCode the most feature rich Medical Coding Solution on the market. If you are a Pharma, CRO, or Service/Technology provider and want more than a replacement for your current WHODD and MedDRA coding solution please contact Charley at firstname.lastname@example.org. We will be happy to schedule a time to demonstrate why CISYS is becoming the market leader for Medical Coding Solutions. Please visit our website at http://www.cisys.com/Medical-Coding-System.html. For a quick review and comparison of what functionality is provided by all the certified providers of medical coding please go to UMC website. https://www.who-umc.org/media/3266/b3-and-c3-format-certified-software-systems.pdf